ReviewClinical medicine (London, England)2026
Update in asthma management: A narrative review of recent advances, challenges, and future directions.
Review in Clinical medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma is a heterogeneous chronic respiratory disease with persistent morbidity and mortality despite effective therapies. The UK continues to report high asthma-related deaths, underscoring the need for improved care.
objectiveTo review recent advances in asthma management, identify ongoing challenges, and outline future directions for clinical practice.
methodsThis narrative review integrates recent guideline updates (BTS/SIGN 2024, GINA 2024), audit data (NACAP), and emerging evidence on diagnostics, phenotype-driven therapy, and novel treatments.
findingsInnovations include biomarker-guided phenotyping, anti-inflammatory reliever (AIR) therapy, biologics targeting type 2 inflammation, and structured frameworks like A2BCD. Foundational care-such as adherence, inhaler technique, and self-management-remains essential. Systemic improvements, including virtual wards and the BTS Asthma4 bundle, enhance continuity of care. The NHS Green Agenda supports sustainable asthma practices.
conclusionsAsthma care is evolving toward personalised, integrated, and environmentally conscious approaches. Clinicians should combine precision therapies with system-level strategies to optimise outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.